
Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Behavioral Parent Training to Address Early Childhood Disruptive Behavior Using the Helping Our Tod1
University of South Florida
Disruptive Behavior
Developmental Disability
Developmental Delay (Disorder)
Behavior Problem of Childhood
HOT DOCS and DOCS K-5 are group-delivered behavioral parent training interventions for
caregivers of children ages 0-12 years. expand
HOT DOCS and DOCS K-5 are group-delivered behavioral parent training interventions for caregivers of children ages 0-12 years. Type: Interventional Start Date: Oct 2018 |
|
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
Narcolepsy Type 2
The purpose of this study is to measure decreases in daytime sleepiness, and disease
symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
compared with placebo tablets. expand
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets. Type: Interventional Start Date: Apr 2026 |
|
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Level1
AbbVie
Healthy Volunteer
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the
single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel. expand
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel. Type: Interventional Start Date: Mar 2026 |
|
Community Health Adaptation & Resilience Mobilization (CHARM) HeatWise
Public Health Institute, California
Heat Illness
Extreme heat events pose serious health risks, especially for communities with limited
access to cooling, transportation, or social support. This study pilots and tests
HEATwise, a heat preparedness program delivered at trusted community centers in Lake
County, California, serving older adults, Tri1 expand
Extreme heat events pose serious health risks, especially for communities with limited access to cooling, transportation, or social support. This study pilots and tests HEATwise, a heat preparedness program delivered at trusted community centers in Lake County, California, serving older adults, Tribal members, and people experiencing housing or economic hardship. HEATwise is a 12-week program which includes a group workshop on heat risks and preparedness, one-on-one resource navigation, a community celebration event, and a cooling and emergency supply kit. The pilot phase (2026) will assess feasibility and acceptability at three sites with approximately 60 participants. The full trial (2027-2028) will randomly assign eight sites to receive HEATwise immediately or after a delay, measuring whether the program increases protective behaviors, reduces heat-related symptoms, and strengthens resilience over 12 months. Type: Interventional Start Date: Apr 2026 |
|
Baby Steps to Care
University Hospitals Cleveland Medical Center
Prenatal Follow Up Care
The purpose of this research study is to understand if receipt of extra prenatal
resources from the ED visit improves i) the patient's ability to engage in prenatal
services after the ED visit, and ii) how it impacts the patient's pregnancy knowledge and
confidence. If participant's consent to this1 expand
The purpose of this research study is to understand if receipt of extra prenatal resources from the ED visit improves i) the patient's ability to engage in prenatal services after the ED visit, and ii) how it impacts the patient's pregnancy knowledge and confidence. If participant's consent to this study, the participants will receive standard of care and additionally be randomized, like flipping a coin, to receive either i) extra prenatal care resources in the form of a 'care box' during this ED visit, or ii) the extra prenatal care resources in the form of a 'care box" two weeks from today. All participants will also receive a follow-up survey asking about the patient's engagement in prenatal services following ED visit, perceptions of pregnancy knowledge and confidence, the usefulness of the resources received, and what additional resources might have been helpful during the early stages of pregnancy. Participation in this study will not require any additional clinic or hospital visits. The total time involved is approximately 20 minutes during the initial ED visit and less than 20 minutes to complete the follow-up survey. Investigators hope to enroll a total of 50 participants in this study. Type: Interventional Start Date: Apr 2026 |
|
Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot1
Ayu, Inc.
Diabetic Foot Ulcer (DFU)
Granulation of Chronic Diabetic Wounds
The objective of this study is to evaluate the safety and efficacy of VELGRAFT in
patients with chronic diabetic foot ulcers, which have attained granulation tissue.
VELGRAFT will be studied in conjunction with pest practices for diabetic foot ulcers. The
Primary goal is to assess the safety of VEL1 expand
The objective of this study is to evaluate the safety and efficacy of VELGRAFT in patients with chronic diabetic foot ulcers, which have attained granulation tissue. VELGRAFT will be studied in conjunction with pest practices for diabetic foot ulcers. The Primary goal is to assess the safety of VELGRAFT to treat diabetic foot ulcers as compared to standard of care therapy. Secondary goals include the assessment of efficacy of VELGRAFT for healing diabetic foot ulcers compared to standard of care therapy Type: Interventional Start Date: Mar 2026 |
|
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Johns Hopkins University
Multiple Sclerosis
The goal of this clinical trial is to evaluate if the study drug will reduce brain and
retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in
people with Multiple Sclerosis. The main outcome for the trial is change in normalized
brain parenchymal volume (nBPV), measu1 expand
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI). Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy). Type: Interventional Start Date: Apr 2026 |
|
A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compare1
HALEON
Denture Retention
The aim of the proposed clinical study is to investigate the efficacy of three
experimental denture adhesive creams to improve denture hold over a period of 13 hours. expand
The aim of the proposed clinical study is to investigate the efficacy of three experimental denture adhesive creams to improve denture hold over a period of 13 hours. Type: Interventional Start Date: Mar 2026 |
|
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning T1
Masonic Cancer Center, University of Minnesota
AML
MDS
Acute Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2)
preparative regimen followed by a related, unrelated, or partially matched family donor
stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus
and MMF for GVHD prophylaxis. expand
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis. Type: Interventional Start Date: Apr 2026 |
|
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
TRIANA Biomedicines, Inc.
ALK-positive NSCLC
ALK-Positive Lung Cancer
ALK-positive Non-small Cell Lung Cancer
The goal of this clinical trial is to learn about the safety and recommended dose of
TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC).
The trial will also evaluate the antitumor activity of TRI-611 in adults with
ALK-positive NSCLC.
The study will be conduct1 expand
The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: - Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing - Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter - Keep a diary of each time they take the study medication Type: Interventional Start Date: Mar 2026 |
|
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart F1
University of Michigan
Heart Failure With Reduced Ejection Fraction
The purpose of this trial is to better understand how the beta-blocker metoprolol works
in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to
participants genetics. Participants will have the beta-blocker (BB) polygenic score
calculated from genotype data. The score will1 expand
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: - HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. - HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. - HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score. Type: Interventional Start Date: Apr 2026 |
|
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
Merck Sharp & Dohme LLC
Psoriatic Arthritis
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will
help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of
active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in
adult participants with active PsA1 expand
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine. Type: Interventional Start Date: Apr 2026 |
|
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Polycythemia Vera (PV)
Myelofibrosis (MF)
Myeloproliferative Neoplasms (MPNs)
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the
safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in
participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to
determine the maximum tolerated dose (MTD) and1 expand
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s). Type: Interventional Start Date: Apr 2026 |
|
Racial Disparities in the Expression of Paranoia
Indiana University
Paranoia
Psychotic Disorders
Paranoia is a pattern of thinking in which people feel suspicious or believe others may
want to harm them. It can occur in many people, not only those with a mental health
diagnosis, and it can affect daily life, relationships, and overall well-being. Research
has consistently shown that Black Amer1 expand
Paranoia is a pattern of thinking in which people feel suspicious or believe others may want to harm them. It can occur in many people, not only those with a mental health diagnosis, and it can affect daily life, relationships, and overall well-being. Research has consistently shown that Black Americans report higher levels of paranoia than White Americans, even when they do not have a clinical diagnosis. However, the reasons for this difference are not well understood. The goal of this study is to better understand why these differences exist. In the experimental part of the study, researchers will use a randomized design to test whether exposure to stressful experiences related to race leads to higher levels of paranoia among Black American participants. The study will also examine factors that may strengthen or weaken this effect, such as individual experiences and personal characteristics. By identifying how stressful experiences related to race influence paranoia, this research aims to improve how paranoia is measured and understood across different groups. These findings may help researchers and clinicians use more accurate and culturally appropriate tools to assess psychosis-related experiences in diverse populations. Type: Interventional Start Date: Apr 2026 |
|
Body Clocks - Coordination of Peripheral and Central Oscillators
Stanford University
Circadian Dysregulation
The investigators are conducting an observational trial examining young women over the
course of 28 days in which we are monitoring movement, sleep, heart rate, oxygen
saturation, gut physiology, light, and menstrual cycle. The inter- and independence of
the cyclicity of these variables with each o1 expand
The investigators are conducting an observational trial examining young women over the course of 28 days in which we are monitoring movement, sleep, heart rate, oxygen saturation, gut physiology, light, and menstrual cycle. The inter- and independence of the cyclicity of these variables with each other, the circadian cycle, the menstrual cycle, and the sleep cycle will be tested. Type: Observational Start Date: Apr 2026 |
|
Evaluation of a Novel mHealth Intervention for People Who Are Ambivalent About Quitting Smoking
Kaiser Permanente
Smoking Behaviors
The goal of this study is to compare the effectiveness of two smoking cessation programs
to determine which better helps people change their smoking behavior, the control or the
experimental intervention? Both interventions include access to a mHealth app and other
publicly available stop-smoking r1 expand
The goal of this study is to compare the effectiveness of two smoking cessation programs to determine which better helps people change their smoking behavior, the control or the experimental intervention? Both interventions include access to a mHealth app and other publicly available stop-smoking resources. The two app versions each include best practice advice and guidance for quitting smoking, but one includes additional content designed for people who aren't ready to quit smoking. The investigators hypothesize that people who receive the experimental intervention will be more likely to request additional stop-smoking resources offered through the intervention and report smoking abstinence after 6 months. The investigators also hypothesize people assigned to the experimental app will have better app engagement and be more likely to report positive changes in their smoking behavior and use of other evidence-based stop smoking treatments that are publicly available. Type: Interventional Start Date: Mar 2026 |
|
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
Post Traumatic Stress Disorder
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD.
Eligible participants will enter a 4-week Treatment Period where they will be randomized
1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the
Treatment Period, participants will ente1 expand
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period. Type: Interventional Start Date: Apr 2026 |
|
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
Narcolepsy Type 1
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy
(sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking
ALKS 2680 tablets compared with placebo tablets. expand
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets. Type: Interventional Start Date: Apr 2026 |
|
Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors
Memorial Sloan Kettering Cancer Center
Cancer
Survivorship
The purpose of this study is to evaluate different combinations of cancer education
sessions, counseling sessions, and peer support meetings developed for Chinese cancer
patients and survivors. The researchers will look at whether the combinations are
practical and effective, and how they impact pa1 expand
The purpose of this study is to evaluate different combinations of cancer education sessions, counseling sessions, and peer support meetings developed for Chinese cancer patients and survivors. The researchers will look at whether the combinations are practical and effective, and how they impact participants' quality of life. Type: Interventional Start Date: Feb 2026 |
|
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
Washington University School of Medicine
Cervical Cancer
HPV Infection
This study is testing and implementing an equity-focused, community-based intervention
that improves women's access to cervical cancer screening and adherence to follow up
after an abnormal result. The study's objective is to assess and compare the feasibility
of different methods of distributing a1 expand
This study is testing and implementing an equity-focused, community-based intervention that improves women's access to cervical cancer screening and adherence to follow up after an abnormal result. The study's objective is to assess and compare the feasibility of different methods of distributing at-home HPV testing kits for cervical cancer screening among individuals who are under-screened. Type: Interventional Start Date: Apr 2026 |
|
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Afliberc1
EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
DME
Diabetic Macular Edema (DME)
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901
against Aflibercept. expand
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept. Type: Interventional Start Date: Feb 2026 |
|
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selno1
Genentech, Inc.
Atherosclerosis
The main purpose of the study is to evaluate the efficacy of selnoflast compared with
placebo in participants with atherosclerosis, at high-risk for major adverse
cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy. expand
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy. Type: Interventional Start Date: Apr 2026 |
|
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Muta1
Oncolytics Biotech
Ras-mutated Metastatic Colorectal Cancer
mCRC
MSS Metastatic Colorectal Cancer
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and
safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with
RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based
therapy. expand
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy. Type: Interventional Start Date: Apr 2026 |
|
Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk
University of Hawaii
Gestational Diabetes Mellitus (GDM)
Pregnancy
This investigator-initiated, non-randomized pilot study evaluates the effect of daily
consumption of fermented poi on the maternal microbiome and gestational diabetes risk
during pregnancy. Fifty pregnant participants between approximately 12 and 24 weeks of
gestation will receive one pound of poi1 expand
This investigator-initiated, non-randomized pilot study evaluates the effect of daily consumption of fermented poi on the maternal microbiome and gestational diabetes risk during pregnancy. Fifty pregnant participants between approximately 12 and 24 weeks of gestation will receive one pound of poi daily for four weeks, accompanied by culturally tailored nutrition education delivered via secure text messaging. Changes in vaginal, oral, and rectal microbiome composition, diet quality, gestational diabetes diagnosis, and pregnancy-related outcomes will be assessed and compared with matched controls derived from an existing cohort. This study aims to inform the feasibility and design of a larger culturally grounded dietary intervention for gestational diabetes prevention. Type: Interventional Start Date: Apr 2026 |
|
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
Eli Lilly and Company
Healthy
The main purpose of this study is to assess the safety and tolerability of mirikizumab
(LY3074828) solution formulation administered as a single injection compared with two
injections under the skin in healthy participants. Blood tests will be performed to
investigate how the body processes the stu1 expand
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks. Type: Interventional Start Date: Mar 2026 |